Prof. Amnon Peled

Silexion Therapeutics Corp. (“Silexion”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. A globally recognized expert in stem cell biology, immunology, and cancer therapeutics, Prof. Peled brings decades of experience in advancing novel cancer treatments from discovery to FDA approval.

Prof. Peled will also serve on Silexion’s audit, compensation, and nominating and corporate governance committees. His appointment reinforces the company’s commitment to scientific and strategic excellence as it advances its RNAi platform and next-generation KRAS-targeting therapies.

In addition to strengthening the Board’s expertise in clinical development and regulatory pathways, Prof. Peled’s appointment ensures Silexion remains in compliance with Nasdaq’s listing requirements by maintaining a fully constituted audit committee.